- Title
- Airway epithelial-targeted nanoparticles for asthma therapy
- Creator
- Kan, Stanislav; Hariyadi, Dewi Melani; Grainge, Christopher Grainge; Knight, Darryl A.; Bartlett, Nathan W.; Liang, Mingtao
- Relation
- American Journal of Physiology: Lung Cellular and Molecular Physiology Vol. 318, Issue 3, p. L500-L509
- Publisher Link
- http://dx.doi.org/10.1152/ajplung.00237.2019
- Publisher
- American Physiological Society
- Resource Type
- journal article
- Date
- 2020
- Description
- Asthma is a common chronic inflammatory disease associated with intermittent airflow obstruction caused by airway inflammation, mucus overproduction, and bronchial hyperresponsiveness. Despite current treatment and management options, a large number of patients with asthma still have poorly controlled disease and are susceptible to acute exacerbations, usually caused by a respiratory virus infection. As a result, there remains a need for novel therapies to achieve better control and prevent/treat exacerbations. Nanoparticles (NPs), including extracellular vesicles (EV) and their synthetic counterparts, have been developed for drug delivery in respiratory diseases. In the case of asthma, where airway epithelium dysfunction, including dysregulated differentiation of epithelial cells, impaired barrier, and immune response, is a driver of disease, targeting airway epithelial cells with NPs may offer opportunities to repair or reverse these dysfunctions with therapeutic interventions. EVs possess multiple advantages for airway epithelial targeting, such as their natural intrinsic cell-targeting properties and low immunogenicity. Synthetic NPs can be coated with muco-inert polymers to overcome biological barriers such as mucus and the phagocytic response of immune cells. Targeting ligands could be also added to enhance targeting specificity to epithelial cells. The review presents current understanding and advances in NP-mediated drug delivery to airway epithelium for asthma therapy. Future perspectives in this therapeutic strategy will also be discussed, including the development of novel formulations and physiologically relevant preclinical models.
- Subject
- airway epithelial targeting; asthma therapy; extracellular vesicles; nanoparticles; pulmonary drug delivery
- Identifier
- http://hdl.handle.net/1959.13/1422806
- Identifier
- uon:37877
- Identifier
- ISSN:1040-0605
- Language
- eng
- Full Text
- Reviewed
- Hits: 4285
- Visitors: 4552
- Downloads: 282
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Author final version | 708 KB | Adobe Acrobat PDF | View Details Download |